SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-035225
Filing Date
2022-06-27
Accepted
2022-06-27 16:30:40
Documents
14
Period of Report
2022-06-27
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea162069-8k_virpax.htm   iXBRL 8-K 24756
2 PRESS RELEASE OF VIRPAX PHARMACEUTICALS, INC. ISSUED JUNE 27, 2022 ea162069ex99-1_virpax.htm EX-99.1 8863
3 GRAPHIC ex99-1_001.jpg GRAPHIC 2465
  Complete submission text file 0001213900-22-035225.txt   214896

Data Files

Seq Description Document Type Size
4 XBRL LABEL FILE vrpx-20220627_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE vrpx-20220627_pre.xml EX-101.PRE 22367
6 XBRL SCHEMA FILE vrpx-20220627.xsd EX-101.SCH 2971
8 EXTRACTED XBRL INSTANCE DOCUMENT ea162069-8k_virpax_htm.xml XML 3720
Mailing Address 1554 PAOLI PIKE #279 WEST CHESTER PA 19380
Business Address 1554 PAOLI PIKE #279 WEST CHESTER PA 19380 484-875-3195
Virpax Pharmaceuticals, Inc. (Filer) CIK: 0001708331 (see all company filings)

IRS No.: 821510982 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40064 | Film No.: 221044976
SIC: 2834 Pharmaceutical Preparations